Secondary prevention after stroke/transient ischemic attack: A randomized audit and feedback trial

2019 ◽  
Vol 140 (2) ◽  
pp. 107-115 ◽  
Author(s):  
Lukas Geary ◽  
Jan Hasselström ◽  
Axel Carl Carlsson ◽  
Irene Eriksson ◽  
Mia von Euler
Keyword(s):  
Secondary Prevention ◽  
Transient Ischemic Attack ◽  
Audit And Feedback ◽  
Feedback Trial ◽  
Ischemic Attack

2014 Chinese guidelines for secondary prevention of ischemic stroke and transient ischemic attack

2017 ◽  
Vol 12 (3) ◽  
pp. 302-320 ◽  
Author(s):  
Yongjun Wang ◽  
Ming Liu ◽  
Chuanqiang Pu
Keyword(s):  
Ischemic Stroke ◽  
Secondary Prevention ◽  
Transient Ischemic Attack ◽  
Recurrent Stroke ◽  
Stroke Recurrence ◽  
Evidence Based ◽  
Cerebrovascular Disorder ◽  
Level Of Evidence ◽  
Vascular Stenosis ◽  
Ischemic Attack

Ischemic stroke and transient ischemic attack (TIA) are the most common cerebrovascular disorder and leading cause of death in China. The Effective secondary prevention is the vital strategy for reducing stroke recurrence. The aim of this guideline is to provide the most updated evidence-based recommendation to clinical physicians from the prior version. Control of risk factors, intervention for vascular stenosis/occlusion, antithrombotic therapy for cardioembolism, and antiplatelet therapy for noncardioembolic stroke are all recommended, and the prevention of recurrent stroke in a variety of uncommon causes and subtype provided as well. We modified the level of evidence and recommendation according to part of results from domestic RCT in order to facility the clinical practice.

scholarly journals Secondary prevention of transient ischemic attack and stroke

2000 ◽  
Vol 173 (4) ◽  
pp. 254-258
Author(s):  
K. R Lees
Keyword(s):  
Secondary Prevention ◽  
Transient Ischemic Attack ◽  
Ischemic Attack

scholarly journals Cost-effectiveness of New Antiplatelet Regimens Used as Secondary Prevention of Stroke or Transient Ischemic Attack

2000 ◽  
Vol 160 (18) ◽  
pp. 2773 ◽  
Author(s):  
François P. Sarasin ◽  
Jean-Michel Gaspoz ◽  
Henri Bounameaux
Keyword(s):  
Cost Effectiveness ◽  
Secondary Prevention ◽  
Transient Ischemic Attack ◽  
Ischemic Attack

scholarly journals Chinese Guidelines for the Secondary Prevention of Ischemic Stroke and Transient Ischemic Attack 2010

2012 ◽  
Vol 18 (2) ◽  
pp. 93-101 ◽  
Author(s):  
Yong-Jun Wang ◽  
Su-Ming Zhang ◽  
Liqun Zhang ◽  
Chun-Xue Wang
Keyword(s):  
Ischemic Stroke ◽  
Secondary Prevention ◽  
Transient Ischemic Attack ◽  
Ischemic Attack

scholarly journals Antiplatelet Therapy After Noncardioembolic Stroke

Stroke ◽  
2019 ◽  
Vol 50 (7) ◽  
pp. 1812-1818 ◽  
Author(s):  
Jacoba P. Greving ◽  
Hans-Christoph Diener ◽  
Johannes B. Reitsma ◽  
Philip M. Bath ◽  
László Csiba ◽  
...  
Keyword(s):  
Secondary Prevention ◽  
Major Bleeding ◽  
Transient Ischemic Attack ◽  
Clinical Benefit ◽  
Antiplatelet Agents ◽  
Vascular Events ◽  
Subgroup Analyses ◽  
Ischemic Attack ◽  
Net Clinical Benefit

Background and Purpose— We assessed the efficacy and safety of antiplatelet agents after noncardioembolic stroke or transient ischemic attack and examined how these vary according to patients’ demographic and clinical characteristics. Methods— We did a network meta-analysis (NMA) of data from 6 randomized trials of the effects of commonly prescribed antiplatelet agents in the long-term (≥3 months) secondary prevention of noncardioembolic stroke or transient ischemic attack. Individual patient data from 43 112 patients were pooled and reanalyzed. Main outcomes were serious vascular events (nonfatal stroke, nonfatal myocardial infarction, or vascular death), major bleeding, and net clinical benefit (serious vascular event or major bleeding). Subgroup analyses were done according to age, sex, ethnicity, hypertension, qualifying diagnosis, type of vessel involved (large versus small vessel disease), and time from qualifying event to randomization. Results— Aspirin/dipyridamole combination (RR NMA-adj , 0.83; 95% CI, 0.74–0.94) significantly reduced the risk of vascular events compared with aspirin, as did clopidogrel (RR NMA-adj , 0.88; 95% CI, 0.78–0.98), and aspirin/clopidogrel combination (RR NMA-adj , 0.83; 95% CI, 0.71–0.96). Clopidogrel caused significantly less major bleeding and intracranial hemorrhage than aspirin, aspirin/dipyridamole combination, and aspirin/clopidogrel combination. Aspirin/clopidogrel combination caused significantly more major bleeding than aspirin, aspirin/dipyridamole combination, and clopidogrel. Net clinical benefit was similar for clopidogrel and aspirin/dipyridamole combination (RR NMA-adj , 0.99; 95% CI, 0.93–1.05). Subgroup analyses showed no heterogeneity of treatment effectiveness across prespecified subgroups. The excess risk of major bleeding associated with aspirin/clopidogrel combination compared with clopidogrel alone was higher in patients aged <65 years than it was in patients ≥65 years (RR NMA-adj , 3.9 versus 1.7). Conclusions— Results favor clopidogrel and aspirin/dipyridamole combination for long-term secondary prevention after noncardioembolic stroke or transient ischemic attack, regardless of patient characteristics. Aspirin/clopidogrel combination was associated with a significantly higher risk of major bleeding compared with other antiplatelet regimens.

Feasibility of treating hyperfibrinogenemia with intermittently administered batroxobin in patients with ischemic stroke/transient ischemic attack for secondary prevention

2007 ◽  
Vol 18 (2) ◽  
pp. 193-197 ◽  
Author(s):  
Gelin Xu ◽  
Xinfeng Liu ◽  
Wusheng Zhu ◽  
Qin Yin ◽  
Renliang Zhang ◽  
...  
Keyword(s):  
Ischemic Stroke ◽  
Secondary Prevention ◽  
Transient Ischemic Attack ◽  
Ischemic Attack

Abstract WP186: The Quality of Secondary Prevention after Stroke or Transient Ischemic Attack is Worse in Survivors With Disability

Stroke ◽  
2018 ◽  
Vol 49 (Suppl_1) ◽  
Author(s):  
Muideen T Olaiya ◽  
Dominique A Cadilhac ◽  
Joosup Kim ◽  
Velandai K Srikanth ◽  
David Ung ◽  
...  
Keyword(s):  
Secondary Prevention ◽  
Transient Ischemic Attack ◽  
Ischemic Attack

Antiplatelet Agents for the Secondary Prevention of Ischemic Stroke or Transient Ischemic Attack: A Network Meta-Analysis

2016 ◽  
Vol 25 (5) ◽  
pp. 1081-1089 ◽  
Author(s):  
Wen Wang ◽  
Lu Zhang ◽  
Weiming Liu ◽  
Qin Zhu ◽  
Qing Lan ◽  
...  
Keyword(s):  
Ischemic Stroke ◽  
Secondary Prevention ◽  
Transient Ischemic Attack ◽  
Meta Analysis ◽  
Antiplatelet Agents ◽  
Ischemic Attack

scholarly journals Pioglitazone for secondary prevention after ischemic stroke and transient ischemic attack: Rationale and design of the Insulin Resistance Intervention after Stroke Trial

2014 ◽  
Vol 168 (6) ◽  
pp. 823-829.e6 ◽  
Author(s):  
Catherine M. Viscoli ◽  
Lawrence M. Brass ◽  
Antonio Carolei ◽  
Robin Conwit ◽  
Gary A. Ford ◽  
...  
Keyword(s):  
Insulin Resistance ◽  
Ischemic Stroke ◽  
Secondary Prevention ◽  
Transient Ischemic Attack ◽  
Ischemic Attack ◽  
Stroke Trial
Sign in / Sign up

Export Citation Format

Share Document